Skip to main content

IBS - Irritable Bowel Syndrome

Gastroenterology
1
Pipeline Programs
6
Companies
8
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Gastroenterology is a $7.3B market characterized by mature, blockbuster-driven portfolios with near-term patent cliff risks.

$7.3B marketMature→ Stable30 products15 companies

Key Trends

  • AbbVie dominance with 43% of top-10 product spending (LINZESS, CREON, RINVOQ)
  • Guanylate cyclase activators and JAK inhibitors driving innovation in constipation and IBD
  • Multiple patent expirations 2026–2030 creating biosimilar and generic erosion headwinds

Career Verdict

Gastroenterology offers stable, well-compensated roles but limited growth upside; best for risk-averse professionals seeking established markets over innovation-driven career trajectories.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1LINZESSStable
$1.8B
AbbVie·Peak7.7yr
#2CREONDeclining
$1.5B
AbbVie·LOE Approaching
#3XIFAXANDeclining
$1.1B
Bausch Health·LOE Approaching
#4RINVOQGrowing
$976M
AbbVie·Peak11.8yr
#5XELJANZ XRStable
$586M
Pfizer·Peak8.3yr

Drug Class Breakdown

Unknown Mechanism
$2.5B(34%)

mature portfolio anchor

Guanylate Cyclase Activators
$1.9B(27%)

well-established class

Pancreatic Enzymes
$1.5B(20%)

facing biosimilar competition

Janus Kinase Inhibitors
$976M(13%)

growing IBD adoption

Proton Pump Inhibitors
$107M(1%)

commoditized

Career Outlook

Stable

Gastroenterology is a stable, mature market anchored by blockbusters with long patent runways (LINZESS to 2034, RINVOQ to 2038) but faces near-term erosion (XELJANZ 2026). Employment growth is modest and concentrated in device/diagnostic firms rather than pure-pharma. Best for professionals seeking predictable revenue streams over high-risk innovation bets.

Breaking In

Target roles at Roche, J&J, or diagnostic-adjacent firms to maximize hiring volume; pure pharma gastro entry points at AbbVie/Pfizer are limited and highly competitive.

For Experienced Professionals

Leverage gastro expertise in broader GI/immunology roles (Takeda, Novartis) or transition to medical devices/diagnostics where hiring is 3x higher than pharma.

In-Demand Skills

IBD and IBS indication expertiseJAK inhibitor pharmacologyMedical device integration (diagnostics, endoscopy)Generic/biosimilar launch readinessReal-world evidence generation

Best For

Medical Science Liaison (IBD/IBS focus)Commercial Manager (Generic Launch)Clinical Operations SpecialistMarket Access/Reimbursement StrategistRegulatory Affairs (small molecule focus)

Hiring Landscape

$70K-$213K

Total hiring across the gastro ecosystem is 1,818 jobs, dominated by engineering (434) and commercial roles (269). Roche leads absolute hiring at 377 roles, followed by Johnson & Johnson (323) and GE HealthCare (293), reflecting broad medical device and diagnostic involvement alongside pharma. AbbVie's gastro-specific hiring (78 jobs) is modest relative to its portfolio dominance.

1,818
Open Roles
4
Companies Hiring
3
Departments

Top Hiring Companies

377Growing
293Stable
78Stable

By Department

Engineering(24%)
$169K
Commercial(15%)
$176K
Manufacturing(10%)
$213K

Manufacturing and commercial roles command premium salaries ($213K and $176K respectively), but total gastro-pharma hiring is concentrated in Roche and J&J, not pure-play GI companies.

Competitive Landscape

6 companies ranked by most advanced pipeline stage

UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
1
RifaximinPhase 41 trial
Active Trials
NCT04074421Unknown240Est. Dec 2022
Syneos Health
Syneos HealthNC - Morrisville
1 program
Bifidobacterium longumN/A1 trial
Active Trials
NCT05054309Completed146Est. Feb 2025
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
COGNITIVE BEHAVIORAL THERAPYN/A4 trials
Active Trials
NCT07566104Not Yet Recruiting30Est. Dec 2028
NCT07281352Recruiting50Est. Nov 2027
NCT05227612Completed16Est. Sep 2025
+1 more trials
Precision BioSciences
1 program
QiMeiYan ProbioticsN/A1 trial
Active Trials
NCT05900752Completed140Est. Jul 2023
Bioiberica
BioibericaSpain - Barcelona
1 program
turmericN/A1 trial
Active Trials
NCT05016596Completed20Est. Apr 2022
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
RifaximinPHASE_4

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
UNION therapeuticsRifaximin
Angeles TherapeuticsCOGNITIVE BEHAVIORAL THERAPY
Angeles TherapeuticsCOGNITIVE BEHAVIORAL THERAPY
Angeles TherapeuticsCOGNITIVE BEHAVIORAL THERAPY
Precision BioSciencesQiMeiYan Probiotics
Syneos HealthBifidobacterium longum
Angeles TherapeuticsCOGNITIVE BEHAVIORAL THERAPY
Bioibericaturmeric

Clinical Trials (8)

Total enrollment: 734 patients across 8 trials

Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With IBS-D

Start: May 2020Est. completion: Dec 2022240 patients
Phase 4Unknown
NCT07566104Angeles TherapeuticsCOGNITIVE BEHAVIORAL THERAPY

Group PACBT for Depression

Start: Jan 2027Est. completion: Dec 202830 patients
Phase 2Not Yet Recruiting
NCT07281352Angeles TherapeuticsCOGNITIVE BEHAVIORAL THERAPY

RCT of Psilocybin-assisted CBT for Depression

Start: Jan 2026Est. completion: Nov 202750 patients
Phase 1/2Recruiting
NCT05227612Angeles TherapeuticsCOGNITIVE BEHAVIORAL THERAPY

Psilocybin-assisted CBT for Depression

Start: Jun 2023Est. completion: Sep 202516 patients
Phase 1Completed

A Multi-Strain Probiotic Reduces the Frequency of Diarrhea in IBS-D Patients

Start: Jun 2023Est. completion: Jul 2023140 patients
N/ACompleted
NCT05054309Syneos HealthBifidobacterium longum

A Trial to Evaluate the Effects of Bifidobacterium Longum NCC3001 on Intestinal and Psychological Symptoms in Subjects With Irritable Bowel Syndrome

Start: Feb 2022Est. completion: Feb 2025146 patients
N/ACompleted
NCT05155631Angeles TherapeuticsCOGNITIVE BEHAVIORAL THERAPY

Sex Differences in Effectiveness of CBT on IBS Project 3

Start: Dec 2021Est. completion: Jan 202592 patients
N/ACompleted

Postprandial Lipids in IBS and Nutritional Treatment

Start: Nov 2021Est. completion: Apr 202220 patients
N/ACompleted

Related Jobs in Gastroenterology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 734 patients
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.